Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment responses seem to differ, being better in cluster 2 and worse in cluster 5 and 6 (at least for IL23i guselkumab). @RheumNow #EULAR2022 POS1055 https://t.co/QIh2SbJKpa

Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ

Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT

#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq

BRIDGE-PMR (rituximab in PMR) routine care extension to 52w (in #PMRGCAJC one big qu asked was ?sustained benefit) sustained benefit (RR 2.5 GC-free remission) steroid-sparing (PNL 1.6g v 2.3g) & ritux ?cheap enough now but COVID calculus difficult POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL

• The Lancet Rheumatology on Twitter: "NEW RESEARCH—Efficacy of #rituximab i…

What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission, 1/3 had BASDAI >3.5. Treatment unchanged as low disease activity, awaiting effects of current Rx, complaints not related to axSpA, patient preference #EULAR2022 @RheumNow POS0303

Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was greatest for TNFi followed by NSAIDs and csDMARDs. TNFi reduced the proportion of patients (48% to 29%) with depressive symptoms at follow up Webers et al #EULAR2022 @RheumNow POS0304

Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD

• EULAR Abstract Archive

BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA ⭐️ACR50 wk 16 43.9% vs 10% PBO ⭐️PASI 90 wk 16 61% vs. 3% PBO ⭐️separation from wk 4 Safety: fungal injections BKZ > ADA @RheumNow LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb

PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE ⭐️Meets primary endpt: SRI(4) ⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved ⭐️Safety data wo VTE, CVD events Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE @RheumNow https://t.co/3YpPSJcenF

Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl

PAISLEY study Phase 2 RCT Deucravacitinib in SLE meets primary endpoint wk 32 Results for dose 3mg BID: *SRI(4) response 58.2% vs. PBO 34% *LLDAS 36% *CLASI 70% *⬇️ SJC No new safety signal Now waiting for Phase 3 👀 @RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7

Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG

Talking about tapering studies in inflammatory arthritis, but true throughout all of rheumatology: Not all flares are equal. This area is full of nuance, we need to think more closely about how we study them. #EULAR2022 @RheumNow https://t.co/tzqqNZv5Ct

#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR